Drug discovery is a process wherein new drugs are identified for any disease indication. Developing a drug from the stage of discovery to market approval is a lengthy process that contributes to high costs for the developers. The main focus of R&D is the identification of a target and the discovery of some chemical candidates that can activate or block the target. The main reasons for drug failure are the discovered drug candidate’s lack of efficacy and safety, which results in financial losses for the companies. To inhibit such contingencies, the status of an efficient drug discovery process has become critical in the field of drug development.
Major market drivers of drug discovery are the globally expanding population and the rising prevalence of a diverse range of diseases encompassing neurology, cardiovascular disease, oncology, and other chronic disease areas. Some tropical infectious diseases are still in need of appropriate medical interventions. Pharmaceutical solutions are required to meet this challenge and also to overcome severe issues like antibiotic resistance.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Download Sample
A number of ways have been identified and are being explored to strengthen the drug discovery technologies market in future years by facilitating patented innovation on free access platforms, developing new metrics for capturing data from open research, and reforming regulatory guidelines by assigning particular designations to products. Increasing research funding from governmental organizations and pharmaceutical manufacturers and the patent expiration of marketed drugs are the major reasons behind the smooth progress of the drug discovery technology market worldwide. The introduction of new technologies is expected to escalate the market growth in the coming years by efficiently identifying promising drug candidates and reducing the chances of failure.
The use of advanced tools such as text mining and machine learning to speed up the process of discovering and developing new drugs is expected to drive the future drug discovery technologies market. The adoption of artificial intelligence tools and IT solutions in drug discovery for speeding up the research process is likely to influence overall drug discovery technology market growth and the industry landscape. However, overall, huge expenses for drug discovery and delayed processing of stringent government regulations act as restraints on market growth.
The purpose of this research study titled “Drug Discovery Technologies Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” is to provide investors, developers, industry experts, and company executives with exhaustive analysis to enable them to take vital strategic initiatives and decisions related to the prospects in the global drug discovery technologies market. This report encompasses key market dynamics factors for drug discovery, such as driving forces, restraining factors, and major opportunities. This research report also delivers the predominant and future trends in the drug discovery technologies market, which is projected through 2025, along with the CAGR for the period of 2017–2025.
This report categorizes the global drug discovery technologies market in terms of technology type and geographical distribution. On the basis of drug discovery technology type, the market has been segmented into high-throughput screening, biochips, bioinformatics, pharmacogenomics and pharmacogenetics, combinatorial chemistry, nanotechnology, spectroscopy, metabolomics, and others (RNAi, proteomics, epigenetics, and chromatography). This research report provided a cross-sectional analysis of each segment using base year (2016) data to gain a better understanding of the market and forecasted through 2025 with a CAGR taking 2017-2025 into account.
Geographically, the drug discovery technologies market is divided into five major regions and five major region-level markets, which are as follows:
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
This report includes a detailed profile of the major players in the drug discovery technologies market, as well as a detailed explanation of competitive assessment tools such as major agreements, acquisition and merger activities, partnerships and collaborations, market attractiveness assessment, and competitive landscape analysis. The major players profiled in this report are Abbott Laboratories, Inc., Novartis AG, Eli Lily, Affymetrix Inc., AstraZeneca plc., Boehringer Ingelheim, Inc., Bayer Healthcare AG, GlaxoSmithKline LLC, Pfizer, Inc., Sanofi, Albany Molecular Research Inc., and Luminex Corporation.
The following major technologies involved in drug discovery have been discussed in the report:
- High-throughput screening
- Biochips
- Bioinformatics
- Pharmacogenomics and pharmacogenetics
- Combinatorial Chemistry
- Nanotechnology
- Spectroscopy
- Metabolomics
- Others (RNA interference, proteomics, epigenetics, and chromatography)
High-throughput screening (HTS) is the leading segment of the drug discovery technology market. The increasing popularity of HTS is due to its high throughput, higher efficiency, rapid assessment of the biological activity of any drug-like compound, and identification of ligands for pharmacological targets. However, the expensive screening process and requirement of a specialized laboratory might act as challenging factors for the market.
Increasing the adoption of biochip technology in drug discovery with the objective of speeding up the drug discovery process, cutting down the attrition rate, and minimizing the timeline of pipeline drugs Advances in biochip technology, as well as the increased flexibility of array technology, have created enormous opportunities for drug discovery. Bioinformatics technology has been driving the drug discovery market by accelerating drug target identification, screening drug candidates, anticipating drug resistance, and characterizing probable side effects.
Expanding pressure to produce a huge number of drugs in a brief timeframe with minimal risk has brought about intense interest in bioinformatics. Presently, the demand for artificial intelligence platforms is on the rise, as they enable researchers to effectively identify drug targets or screen drug repositioning, which is expected to stimulate the drug discovery technologies market’s growth. Nanotechnology is playing a stellar role in the drug discovery technology market by developing enhanced drug formulations and drug delivery systems while overcoming challenges like inadequate throughput and unreliable data.
Geographically, the global drug discovery technologies market is cumulative for North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In the base year 2016, North America is estimated to be the most significant market for drug discovery technologies as the region is the hub of all major drug manufacturing companies. The adoption of recent advanced technologies is higher in North America, which in turn acts as a driving force for market growth. Increasing expenditure on R&D and promising policies encourage pharmaceutical companies to develop drugs. The United States, being the leader in medical research, produced more than half of all drug molecules in the last decade.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The European Medicines Agency’s PRIME initiative, which launched a fast-track scheme for drug approval, is expected to boost the drug discovery technologies market in this region. Increasing initiatives for collaborative research projects and networking among industrial and academic experts, large pharmaceutical companies, and medium- or small-sized enterprises are expected to support pharmaceutical development in Europe. European Lead Factory is a platform aiming to escalate drug discovery in Europe by providing access to academic institutions and small and medium enterprises with more than 500,000 novel chemical compounds and boosting drug discovery activities. Asia-Pacific is a region with 60% of the world’s population.
This region is expected to witness substantial growth due to the large targeted population and the pool of potential clinical trials it offers. Rising disease prevalence, increasing funding for research activities, and improved regulatory guidelines regarding clinical research are a few of the major drivers of the drug discovery technologies market in the Asia Pacific.
The global market for drug discovery technologies is presented as follows:
- North America (the United States and Canada)
- Europe (the United Kingdom, Germany, and the rest of the European countries)
- Asia Pacific (India, Japan, China, South Korea, and the rest of Asia Pacific countries)
- Latin America (Mexico, Brazil, and the rest of LATAM countries)
- Middle East and Africa (GCC, South Africa, and the rest of the MEA)
